Usefulness of the top-scoring pairs of genes for prediction of prostate cancer progression

Prostate Cancer and Prostatic Diseases

Volumn 13, Issue 3, 2010, Pages 252-259

  Zhao, H ^a   Logothetis, C J ^a   Gorlov, I P ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Cancer progression; Gene co expression; Metastasis; Top scoring pairs of genes

Indexed keywords

BRCA1 PROTEIN; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; GENE PRODUCT; INSULIN RECEPTOR; INTEGRIN; PROTEIN SQLE; PROTEIN TPD52L2; RHO FACTOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CLASSIFICATION ALGORITHM; DATA ANALYSIS; DISTANT METASTASIS; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; PREDICTION; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TOP SCORING PAIR ALGORITHM;

ALGORITHMS; CASE-CONTROL STUDIES; COMPUTATIONAL BIOLOGY; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; HUMANS; MALE; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 77955711890     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2010.9     Document Type: Article

References (30)

1. Burdick MJ, Reddy CA, Ulchaker J, Angermeier K, Altman A, Chehade N et al. Comparison of biochemical relapse-free survival between primary Gleason score 3 and primary Gleason score 4 for biopsy Gleason score 7 prostate cancer. Int J Radiat Oncol Biol Phys 2009; 73: 1439-1445.
2. Freedland SJ, Eastham J, Shore N. Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer. Prostate Cancer and Prostatic Dis 2009; 12: 333-338.
3. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001; 412: 822-826.
4. Dhanasekaran SM, Dash A, Yu J, Maine IP, Laxman B, Tomlins SA et al. Molecular profiling of human prostate tissues: insights into gene expression patterns of prostate development during puberty. FASEB J 2005; 19: 243-245.
5. Nakagawa T, Kollmeyer TM, Morlan BW, Anderson SK, Bergstralh EJ, Davis BJ et al. A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy. PLoS One 2008; 3: e2318.
6. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002; 1: 203-209.
7. Chandran UR, Ma C, Dhir R, Bisceglia M, Lyons-Weiler M, Liang W et al. Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer 2007; 7: 64.
8. LaTulippe E, Satagopan J, Smith A, Scher H, Scardino P, Reuter V et al. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res 2002; 62: 4499-4506.
9. Luo JH, Yu YP, Cieply K, Lin F, Deflavia P, Dhir R et al. Gene expression analysis of prostate cancers. Mol Carcinog 2002; 33: 25-35.
10. Tamura K, Furihata M, Tsunoda T, Ashida S, Takata R, Obara W et al. Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. Cancer Res 2007; 67: 5117-5125.
11. Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 2004; 22: 2790-2799.
12. Ummanni R, Teller S, Junker H, Zimmermann U, Venz S, Scharf C et al. Altered expression of tumor protein D52 regulates apoptosis and migration of prostate cancer cells. FEBS J 2008; 275: 5703-5713.
13. Ding GF, Xu YF, Yang ZS, Ding YL, Fang HF, Zhao HP. Coexpression of the mutated BRCA1 mRNA and p53 mRNA and its association in Chinese prostate cancer. Urol Oncol 2009; doi: 10.1016/j.urolonc.2009.01.002.
14. Schayek H, Haugk K, Sun S, True LD, Plymate SR, Werner H. Tumor suppressor BRCA1 is expressed in prostate cancer and controls insulin-like growth factor I receptor (IGF-IR) gene transcription in an androgen receptor-dependent manner. Clin Cancer Res 2009; 15: 1558-1565.
15. Tilki D, Irmak S, Oliveira-Ferrer L, Hauschild J, Miethe K, Atakaya H et al. CEA-related cell adhesion molecule-1 is involved in angiogenic switch in prostate cancer. Oncogene 2006; 25: 4965-4974.
16. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007; 39: 41-51.
17. Geman D, D'Avignon C, Naiman DQ, Winslow RL. Classifying gene expression profiles from pairwise mRNA comparisons. Stat Appl Genet Mol Biol 2004; 3, Article 19.
18. Tan AC, Naiman DQ, Xu L, Winslow RL, Geman D. Simple decision rules for classifying human cancers from gene expression profiles. Bioinformatics 2005; 21: 3896-3904.
19. Xu L, Tan AC, Naiman DQ, Geman D, Winslow RL. Robust prostate cancer marker genes emerge from direct integration of inter-study microarray data. Bioinformatics 2005; 21: 3905-3911.
20. Ummanni R, Teller S, Junker H, Zimmermann U, Venz S, Scharf C et al. Altered expression of tumor protein D52 regulates apoptosis and migration of prostate cancer cells. FEBS J 2008; 275: 5703-5713.
21. Cheng I, Plummer SJ, Jorgenson E, Liu X, Rybicki BA, Casey G et al. 8q24 and prostate cancer: association with advanced disease and meta-analysis. Eur J Hum Genet 2008; 16: 496-505.
22. Hooker S, Hernandez W, Chen H, Robbins C, Torres JB, Ahaghotu C et al. Replication of prostate cancer risk loci on 8q24, 11q13, 17q12, 19q33, and Xp11 in African Americans. Prostate 2009; doi: 10.1002/pros.21061.
23. Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P, Wacholder S et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007; 39: 645-649.
24. Antognelli C, Mearini L, Talesa VN, Giannantoni A, Mearini E. Association of CYP17, GSTP1, and PON1 polymorphisms with the risk of prostate cancer. Prostate 2005; 63: 240-251.
25. Schayek H, Haugk K, Sun S, True LD, Plymate SR, Werner H. Tumor suppressor BRCA1is expressed in prostate cancer and controls insulin-like growth factor I receptor (IGF-IR) gene transcription in an androgen receptor-dependent manner. Clin Cancer Res 2009; 15: 1558-1565.
26. Xu W, Liu LZ, Loizidou M, Ahmed M, Charles IG. The role of nitric oxide in cancer. Cell Res 2002; 12: 311-320.
27. Cronauer MV, Ince Y, Engers R, Rinnab L, Weidemann W, Suschek CV et al. Nitric oxide-mediated inhibition of androgen receptor activity: possible implications for prostate cancer progression. Oncogene 2007; 26: 1875-1884.
28. Kroncke KD, Suschek CV, Kolb-Bachofen V. Implications of inducible nitric oxide synthase expression and enzyme activity. Antioxid Redox Signal 2000; 2: 585-605.
29. Moon YJ, Wang X, Morris ME. Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. Toxicol In Vitro 2006; 20: 187-210.
30. Okamura M, Yamaji S, Nagashima Y, Nishikawa M, Yoshimoto N, Kido Y et al. Prognostic value of integrin b1-ILK-pAkt signaling pathway in non-small cell lung cancer. Hum Pathol 2007; 38: 1081-1091.